Biotechnology - ACADIA Pharmaceuticals


Current filters:

ACADIA Pharmaceuticals

Popular Filters

Positive new Ph III data for ACADIA Pharma’s pimavanserin in Parkinson’s


US biotech firm ACADIA Pharmaceuticalssays that new date published in the on-line edition of The Lancet…

ACADIA PharmaceuticalsBiotechnologyBiovailNeurologicalpimavanserinResearch

FDA backs NDA filing for ACADIA's Parkinson's candidate pimavanserin


US biotech firm ACADIA Pharmaceuticals (Nasdaq: ACAD) saw its shares leap 42.8% to $7.97 in pre-market…

ACADIA PharmaceuticalsBiotechnologyNeurologicalNorth AmericapimavanserinRegulation

Back to top